Email: cspc@cspc.cn
News
News Center
Jan. 29
2026
VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jan. 13
VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jan. 12
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS
Jan. 02
VOLUNTARY ANNOUNCEMENT - NINTEDANIB ESILATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Dec. 12
2025
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR DUOENYI (IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS MARKETING APPROVAL
Dec. 10
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
